Molecular interactions involving urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), as new targets for tumour therapy

Author： Frankenne F.   Noel A.   Bajou K.   Sounni N.   Goffin F.   Masson V.   Munaut C.   Remacle A.   Foidart J.  

Publisher： Informa Healthcare

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.3, Iss.3, 1999-09, pp. : 469-481

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Urokinase-type Plasminogen Activator (uPA) and its Receptor (uPAR): Development of Antagonists of uPA / uPAR Interaction and their Effects In Vitro and In Vivo

By  

Current Pharmaceutical Design, Vol. 9, Iss. 19, 2003-07 ,pp. : 1529-1543

Bentham Science Publishers

Access to resources Recommend Favorite

Plasminogen Activator Inhibitor-1

By  

Current Medicinal Chemistry, Vol. 11, Iss. 17, 2004-09 ,pp. : 2323-2334

Bentham Science Publishers

Access to resources Recommend Favorite

Development of Novel Therapeutics Targeting the Urokinase Plasminogen Activator Receptor (uPAR) and Their Translation Toward the Clinic

By  

Current Pharmaceutical Design, Vol. 17, Iss. 19, 2011-06 ,pp. : 1970-1978

Bentham Science Publishers

Access to resources Recommend Favorite

The status of plasminogen activator inhibitor-1

By Charlton P.  

Expert Opinion on Investigational Drugs, Vol. 6, Iss. 5, 1997-05 ,pp. : 539-554

Informa Healthcare

Access to resources Recommend Favorite

3D-QSAR Studies on Isocoumarin-based Urokinase-type Plasminogen Activator (uPA) Inhibitors Employing Linear and Non-linear Regression Analysis Methods

By  

Letters in Drug Design & Discovery, Vol. 9, Iss. 9, 2012-11 ,pp. : 874-880

Bentham Science Publishers

Access to resources Recommend Favorite